We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Randomized Clinical Trial of Adipose-Derived Stem Cells in the Treatment of Pts With ST-elevation Myocardial Infarction

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: March 2, 2007
Last Update Posted: November 26, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Cytori Therapeutics
The purpose of this study is to establish safety and feasibility of utilizing Adipose-Derived Stem and Regenerative Cells (ADRC's) in patients who have suffered a ST-elevation acute myocardial infarction.

Condition Intervention Phase
Myocardial Infarction Coronary Arteriosclerosis Cardiovascular Disease Coronary Disease Drug: Injection of ADRC's Other: Injection of Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Clinical Trial of AdiPOse-derived Stem ceLLs in the Treatment of Patients With ST-elevation myOcardial Infarction - The APOLLO Trial

Resource links provided by NLM:

Further study details as provided by Cytori Therapeutics:

Primary Outcome Measures:
  • Safety - Determined by Major Adverse Cardiac and Cerebral Events (MACCE) [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Feasibility - Assessment of cardiac function via functional and imaging studies including MRI, SPECT, and Echocardiography [ Time Frame: 6 months ]

Enrollment: 14
Study Start Date: November 2007
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo is injected
Other: Injection of Placebo
Placebo is injected
Experimental: Treatment
ADRC's are injected
Drug: Injection of ADRC's
ADRC's are injected

Detailed Description:
Subjects who have coronary artery disease and have suffered a ST-elevation acute myocardial infarction will be evaluated for eligibility in this study. Eligible subjects will undergo standard treatment after admission to the hospital and will then undergo liposuction under local anesthesia, after which ADRC's will be isolated from the lipoaspirate. According to randomization subjects will receive either ADRC's or placebo.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Acute myocardial infarction (AMI)
  • Clinical symptoms consistent with AMI for a minimum of 2 and a maximum of 12 hours from onset of symptoms to Percutaneous Coronary Intervention (PCI), and unresponsive to nitroglycerin
  • Successful revascularization of the culprit lesion in the major epicardial vessel
  • Area of hypo- or akinesia corresponding to the culprit lesion, as determined by left ventriculogram at the time of primary PCI
  • Left ventricular ejection fraction (LVEF) ≥30% and ≤50% by Left Ventricular Angiography at the time of successful revascularization.
  • Ability to undergo liposuction

Key Exclusion Criteria:

  • Prior MI, prior known cardiomyopathy, or prior hospital admission for congestive heart failure (CHF)
  • More than 24 hours after acute PCI
  • Significant valvular disease
  • More than twelve hours between the onset of first symptoms of AMI and revascularization
  • Hemodynamic instability within 24 hours prior to randomization
  • Neoplasia
  • Acute or chronic bacterial or viral infectious disease
  • Pacemaker, ICD or any other contra-indication for MRI
  • LVEF <30% or >50% by Left Ventricular Angiography
  • Moderate or severe COPD
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00442806

Erasmus University Medical Centrum, Thorax Center
Rotterdam, Netherlands
Hospital General Universitario Gregorio Maranon
Madrid, Spain, 28007
Sponsors and Collaborators
Cytori Therapeutics
Principal Investigator: Eric Duckers, MD, PhD Erasmus University Medical Centrum, ThoraxCenter
  More Information

Responsible Party: Cytori Therapeutics
ClinicalTrials.gov Identifier: NCT00442806     History of Changes
Other Study ID Numbers: APOLLO - 01
First Submitted: February 28, 2007
First Posted: March 2, 2007
Last Update Posted: November 26, 2013
Last Verified: November 2013

Keywords provided by Cytori Therapeutics:
Stem Cells
Myocardial Infarction
Heart Disease
Coronary Artery Disease
Coronary Disease
Interventional Cardiology
Heart Attack

Additional relevant MeSH terms:
Cardiovascular Diseases
Myocardial Infarction
Coronary Disease
Coronary Artery Disease
ST Elevation Myocardial Infarction
Myocardial Ischemia
Pathologic Processes
Heart Diseases
Vascular Diseases
Arterial Occlusive Diseases